JP2022512346A5 - - Google Patents

Info

Publication number
JP2022512346A5
JP2022512346A5 JP2021532849A JP2021532849A JP2022512346A5 JP 2022512346 A5 JP2022512346 A5 JP 2022512346A5 JP 2021532849 A JP2021532849 A JP 2021532849A JP 2021532849 A JP2021532849 A JP 2021532849A JP 2022512346 A5 JP2022512346 A5 JP 2022512346A5
Authority
JP
Japan
Prior art keywords
antibody
cdr
antagonist
activin
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021532849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512346A (ja
JP7660507B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066908 external-priority patent/WO2020131910A1/en
Publication of JP2022512346A publication Critical patent/JP2022512346A/ja
Publication of JP2022512346A5 publication Critical patent/JP2022512346A5/ja
Application granted granted Critical
Publication of JP7660507B2 publication Critical patent/JP7660507B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021532849A 2018-12-18 2019-12-17 レプチン受容体、ｇｄｆ８、およびアクチビンａに対するアンタゴニストを使用して、体重および除脂肪筋肉量を増やすための組成物および方法 Active JP7660507B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862781226P 2018-12-18 2018-12-18
US62/781,226 2018-12-18
PCT/US2019/066908 WO2020131910A1 (en) 2018-12-18 2019-12-17 Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a

Publications (3)

Publication Number Publication Date
JP2022512346A JP2022512346A (ja) 2022-02-03
JP2022512346A5 true JP2022512346A5 (https=) 2022-12-23
JP7660507B2 JP7660507B2 (ja) 2025-04-11

Family

ID=69182653

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021532849A Active JP7660507B2 (ja) 2018-12-18 2019-12-17 レプチン受容体、ｇｄｆ８、およびアクチビンａに対するアンタゴニストを使用して、体重および除脂肪筋肉量を増やすための組成物および方法

Country Status (10)

Country Link
US (1) US20240247071A2 (https=)
EP (1) EP3898672A1 (https=)
JP (1) JP7660507B2 (https=)
KR (1) KR20210104744A (https=)
CN (1) CN113195532B (https=)
AU (1) AU2019401575A1 (https=)
CA (1) CA3123024A1 (https=)
IL (1) IL283748A (https=)
MX (2) MX2021007394A (https=)
WO (1) WO2020131910A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
WO2024064842A1 (en) * 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
US20260000758A1 (en) * 2024-06-28 2026-01-01 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK0690873T3 (da) 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
ATE557042T1 (de) 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
US7307142B2 (en) 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
EP1951756B1 (en) 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
BRPI0716249A2 (pt) 2006-09-05 2013-09-03 Lilly Co Eli anticorpos antimiostatina
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
DK2780368T3 (en) * 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
KR20170135967A (ko) * 2015-04-15 2017-12-08 리제너론 파마슈티칼스 인코포레이티드 Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
LT3538554T (lt) 2016-11-08 2025-10-10 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius

Similar Documents

Publication Publication Date Title
AU2020270555A1 (en) Combination therapy with an anti BCMA antibody and a gamma secretase inhibitor
JP2018512435A5 (https=)
RU2013155906A (ru) Антитела анти-angptl3 и их применение
RU2016136364A (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
FI3810281T3 (fi) Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla
JP2010528047A5 (https=)
JP2022512346A5 (https=)
JP2016519650A5 (https=)
JP2021527640A5 (https=)
JP2010520290A5 (https=)
IL276921B2 (en) Methods for altering body composition
AU2022200690B2 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
JP7660507B2 (ja) レプチン受容体、ｇｄｆ８、およびアクチビンａに対するアンタゴニストを使用して、体重および除脂肪筋肉量を増やすための組成物および方法
JP2023506779A5 (https=)
WO2018234843A1 (en) Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
JP2024540435A5 (https=)
JP2021533142A5 (https=)
JP2024528877A5 (https=)
JP2022549218A5 (https=)
JP2022125157A (ja) 抗－ｖｅｇｆｒ－２抗体
RU2021115714A (ru) Композиции и способы для повышения веса тела и сухоймышечной массы с применением антагонистов рецептора лептина, gdf8 и активина а
JP2024526742A5 (https=)
JP2023551519A5 (https=)
IL311796A (en) Anti-galectin-9 antibodies and their therapeutic uses
IL319160A (en) Methods for treating cancer using anti-CTLA4 antibodies